chrisvoncsefalvay/vaers-outcomes huggingface dataset:
post-herpetic neuralgia; shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient on unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications.  On an unknown date in 2012, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route of administration were not specified) for the long-term prevention of shingles and zoster-related conditions, by a pharmacist in a pharmacy. On an unspecified date, the patient experienced shingles and post-herpetic neuralgia. On an unspecified date, the patient was treated by a healthcare provider for the events. As a direct and proximate result of the patient's use of the zoster vaccine live (ZOSTAVAX) vaccine, he had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future.  The outcome of the events was not reported. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).
Patient did not receive the second dose with in 42 days after the first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of OFF LABEL USE (Patient did not receive the second dose with in 42 days after the first dose) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced OFF LABEL USE (Patient did not receive the second dose with in 42 days after the first dose). At the time of the report, OFF LABEL USE (Patient did not receive the second dose with in 42 days after the first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were provided by the reporter.
Red dime size swollen lump in left leg. Painful to the touch and to walk on leg.
Right anterior thigh: large circumferential area of erythema in target pattern around injection site. Treatment: attempt cool compresses or baths to thigh, attempt leg elevations, weaning course of prednisolone.
At 12-15 hours, fever 101 +, redness, tenderness at injection site and limp.
* Preface note- I took a doctors recommendation and took 100mg of Tylenol immediately prior to vaccination. I now know that is not the best practice.  Diarrhea within a few hours of arriving home. Felt fine otherwise for the rest of that day. Woke up on 1/25 with very achy back, and severe fatigue. As the day went on, I felt increasingly worse, exhaustion and increasing  body aches.  Low fever, 99.9.  Took one more  Tylenol at 7am, and 400mg Advil at 1pm. Increasingly felt general malaise. Stayed in bed. headache, fever continued,  by nightfall, the temp was 101 with drugs on board. The aches turned into joint type pain in my low back, hips and knees.  Fever broke at 10pm with sweating. Went to bed and woke up without the aches, just fatigue which has lasted until 1/27/21.  Finally feel more well today, 1/28/21. No aches, no headache, just sore arm and slight fatigue.
Patient was at her day treatment program and had a two and a half minute seizure while sitting at a table.  She bit her tongue during the seizure.  She slowly came out of the seizure and was out of it for a while and confused.  911 was called due to the length of the seizure and a lack of seizure history. Seizure was two minutes; thirty seconds long about 21 hours after 1st Moderna Covid vaccine.
Date of Admission: 11/28/2022   Date of Discharge: 12/6/2022   Admission Diagnosis: Shock [R57.9] Pain [R52] Septicemia [A41.9]   Hospital Principal Problem (Discharge Diagnoses): Septic shock    All Hospital Problems (Other Diagnoses): Active Hospital Problems   Diagnosis o Principal Problem: Septic shock  o COVID-19 o Unstageable pressure ulcer of left buttock  o Unstageable pressure ulcer of right buttock  o Dermatitis associated with moisture (coccyx, left upper buttock) o Septicemia  o Pain o Encephalopathy o Elevated troponin o LBBB (left bundle branch block) o Lactic acidosis o AKI (acute kidney injury)
Patient noticed tingling around her mouth in parking lot - so she took an ALLEGRA. When arrived at home, throat started to close and tongue swelled so she took 2 BENADRYL and call ambulance.
Throat swelling; Felt she was being chocked; This spontaneous case was received on 02-Oct-2020, from pharmacist via Health Authority (reference number: SEQW20-02845) and concerned a 41-year-old, female patient.     The patient's medical history and concomitant medications were not reported.  On 02-Oct-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent; dose 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 276535 and expiry date was 07-Jun-2021.  On the same date, after receiving Flucelvax QIV, the patient experienced throat swelling and felt she was being choked. The patient was hospitalized and was treated with Benadryl (diphenhydramine hydrochloride), orally and Solumedrol (methylprednisolone sodium succinate). The symptoms were getting better. Reporter stated that did not know if it was fully resolved. The patient was discharged from hospital on the same day.   At the time of initial reporting on 02-Oct-2020, the patient was recovering from the events throat swelling and 'choking sensation'.  The reporter assessed events as non-serious.  The reporter did not provide causality assessment.  This case is linked with 202005024 due to same reporter.  Company comment: The patient developed pharyngeal swelling and choking sensation on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. Reportedly, the patient was hospitalized, was treated with Benadryl orally and Solumedrol, and the symptoms were getting better. The patient was discharged from hospital on the same day. No information about concomitant medications and medical history was provided. Considering all above mentioned, causal relationship for both events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).; Sender's Comments: The patient developed pharyngeal swelling and choking sensation on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. Reportedly, the patient was hospitalized, was treated with Benadryl orally and Solumedrol, and the symptoms were getting better. The patient was discharged from hospital on the same day. No information about concomitant medications and medical history was provided. Considering all above mentioned, causal relationship for both events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).
patient was administered an expired PNEUMOVAX 23; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided.     On 08-SEP-2021, the patient was vaccinated with an expired pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) 0.5 mL, once, lot # T007383, expiration date on 23-AUG-2021, for prophylaxis (route of administration and anatomical location were not reported) (expired product administered).
severe rash on upper left side of back, and partially on inside of  upper left arm;  nurse identified the rash as probable "shingles";  patient has chicken pox as child
Red rashes on all over the body. These red rashes are hives. They still persist on my skin even after so many days of my Booster shot. Treatment: The doctor prescribed Prednisone 20mg tablet, gave a Kenalog-40 shot, and advised to take Cetrizine or Benadryl as required.
2 days after my vaccine, I experiences chest pain, which I would describe as a dull pain in the center of my chest.  I thought it was possibly angina.  I have no previous history of heart disease.  I have had high cholesterol that is managed using Crestor.  In addition, my heart would spike throughout the day to as high as 108 bpm, without significant activity.  My normal resting heart rate is ~74bpm.
the evening of the vaccine both eyes were itchy and dry. friend noticed at about 2pm the next day that right eye very bright and almost solid red on the entre outer half of the white area and inner eye lid (looks bloody); also looks to have some bumps in the red area. I had not looked at myself in the mirror, but I guess it was like that since earlier in the day since my eye felt irritated. I have not used contacts since removing them before bed the night of the vaccine (4/27) Also  experiencing fever of 101.2, and body and head aches, and fatigue
Child started feeling dizzy. Redness and swelling began at injection site about 5 minutes after administering.  Benedryl was administered at the school per the parents request.
Site: Bruising at Injection Site-Severe, Site: Itching at Injection Site-Severe, Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Systemic: Allergic: Rash (specify: facial area, extremeties)-Severe, Systemic: Chest Tightness / Heaviness / Pain-Severe, Systemic: Joint Pain-Severe, Systemic: Tingling (specify: facial area, extemities)-Severe, Additional Details: water like feeling in skin
This literature report was received from the authors of the published article title and concerns 317 patients of unspecified age and gender. On unknown dates, the patients were vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) (Dosing regimen, frequency, lot # and expiration date unknown) subcutaneous for prophylaxis. The author reported that greater than 97% of the patients received a 2-dose measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown). A third dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) was recommended as a control measure. The authors conducted an investigation and identified that the patients had a mumps outbreak between 09-APR-2015 and 27-MAY-2016 despite being vaccinated with 2-dose measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown). The patients were considered to be infectious from 2 days before until 5 days after the onset of parotitis. Among the 317 cases identified, at the time of parotitis onset, 50 mumps patients had received 3 doses of MMR vaccine, 232 had received 2 doses, 12 had received 1 dose, seven were unvaccinated, and 16 had unknown vaccination status. Forty-five of the 50 patients with a third dose received it during this outbreak, and five received it in prior years for reasons unrelated to this outbreak. Some of the 45 persons who received a third dose during this outbreak might have been exposed before vaccine-induced immunity was boosted. Eleven of the 45 patients had parotitis onset on the same day or within 2 weeks after receiving the third dose, six (13%) within 2-4 weeks, and 27 (60%) >4 weeks after. One (2%) patient received a third dose 3 days after parotitis onset. One hundred cases were laboratory confirmed by rRT-PCR, and 217 were classified as probable. Cases occurred in persons who ranged in age from 16-55 years, with a median age of 20 years. Two patients experienced orchitis, a recognized complication of mumps. No deaths were reported. All cases were epidemiologically linked to the university; 278 cases occurred in students, three in staff members, and 36 in persons not affiliated with the university, but who had contact with university students or the campus. Several sub-clusters occurred within the larger outbreak in certain academic programs, athletic facilities, and community workplaces. The outcome of the events was unknown. The reporter considered the events to be related to M-M-R II. Additional information has been requested.
Migraines (ongoing), fevers (occasional), nausea, chills/shakiness, sweats, stomach pains, higher blood pressure. I was taking Ubrelvy, recommended by my PCP, and it seemed to help daily for about a week and then the symptoms just came back. It didn't work for me as well as I had thought.
Admitted to hospital on 2/8/22 with COVID pneumonia.  Patient is a 73 y.o. smoker who has a history of COPD and nocturnal hypoxia, along with CKD 3, diabetes and hypertension presenting with shortness of breath and cough, going on for the last 3 to 4 days.  She is vaccinated but did not receive a booster.  She normally wears oxygen only at night, currently wearing 2 L saturating 96%.  I do not see any documented hypoxia on admission.  She was in atrial flutter with rapid rate when she came in and did receive some IV Lopressor but has now converted to sinus rhythm.  She thinks that she had some history of A. fib but is not sure.  Cough is productive of some thick sputum.  She is feeling a little better since arrival.  She did start a coughing fit when I was in the room and really did not stop the rest of the time I was in there, limited history after that.
The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify. Follow-up information has been received from the practice manager on 18-SEP-2018. This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided. On 15-FEB-2018, the patient was vaccinated with an improperly stored dose of PROQUAD (recombinant Human albumin) (strength and route were unknown) (lot# M044718 and expiration date 07-MAY-2018) for prophylaxis (Incorrect product storage). The sterile diluent (MERCK) was properly stored. No adverse event was reported. The excursion temperature on 22-SEP-2017, 17-OCT-2017, 06-DEC-2017, 07-DEC-2017, 30-JAN-2018, 23-FEB-2018, 18-MAY-2018, 05-JUL-2018, 15-AUG-2018 was 6 degree Celsius for maximize 8.75 hours. The excursion temperature on 02-MAR-2018, 27-AUG-2018 was 7 degree Celsius for maximize 8.75 hours. The excursion temperature on 07-DEC-2017 was 8 degree Celsius for maximize 15 hours. The call was not because of data logger. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1809USA003709: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001956: US-009507513-1810USA001957: US-009507513-1810USA001959.
Hives and itching on my arms, hands, ears, neck, stomach and backs of legs.  This started 4 days after my 2nd Covid dose.  I am taking Benadryl multiple times a day.
Received 2nd dose in series as low Hep B antibody levels and  employment places higher risk of exposure. Second dose as above with labs through PCP with Transaminitis. Repeat labs 2 weeks later better but still high. Third set of labs through occupational health better / resolving. Two sets of viral tests run including Hep b, Hep c and HIV all negative. Liver US normal. No major medical history otherwise. Felt to be related to Hep B vaccine.
COVID-19 positive; different taste in mouth; Initial information received on 30-Jan-2021 regarding an unsolicited valid non-serious case received from a consumer (patient).  This case involved an 81-year-old male patient who experienced covid-19 positive (sars-cov-2 test positive) and different taste in mouth (taste disorder), while patient received vaccines INFLUENZA VACCINE.  Medical history, past medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications were not reported.  On an unknown date, the patient received INFLUENZA VACCINE [lot number: unknown and expiration date: unknown] at an unknown dose via unknown route in an unknown administration site for prophylactic vaccination.  On an unknown date, patient who experienced covid-19 positive (sars-cov-2 test positive) and different taste in mouth (taste disorder) (latency: unknown) following the administration of suspect vaccine.  It was not reported if the patient received a corrective treatment.  Outcome of the event was unknown.  There will be no information available regarding batch number in this case.
Myalgia, Fever, body aches, chills, chest tightness, pain in left upper  arm Narrative:   Other Relevant History:
This spontaneous report was received from a pharmacist via a company representative, concerning two elderly female patients with unknown age. The patient's concurrent conditions and medical history, as well as concomitant medications, were not reported. On an unknown date, the patients were vaccinated with PNEUMOVAX 23 (lot#: N032092, expiration Date: 12-SEP-2019) one dose, once, for pneumonia prevention and FLUAD (strength, dose, route, frequency, lot# and expiration date were unknown) for prophylaxis. On an unknown date, the patients experienced redness and swelling at the injection site (injection site erythema and injection site swelling) that went from shoulder to elbow, the skin at the injection site was painful to touch (injection site pain), and the patients were feeling under the weather with flu-like symptoms that persisted for 3-4 days. At the reporting time, the outcome of injection site pain, flu-like symptoms, injection site erythema and injection site swelling were reported as recovered on an unknown date. The causality between PNEUMOVAX 23 and FLUAD and injection site pain, flu-like symptoms, injection site erythema and injection site swelling were not assessed. This is one of three reports from the same reporter; Sender's Comments: US-009507513-1810USA004434: US-009507513-1810USA006560:
requested pt's medical records, but never received; pt had a positive COVID test on 10/28/21; per death certificate pt passed away in the hospital with the cause of death being COVID 19
Information has been received from a nurse manager concerning a 63 year old female who on 02-MAY-2010 was vaccinated with a first dose of PNEUMOVAX 23 (IM) (lot # 664964/1338Y). "2 days after injection", on 04-MAY-2010 the patient called and stated that the injection site area in the left deltoid was raised and red. The patient was advised to put a cool compress on it and recovered on unspecified date. Additional information has been requested.
Pt fainted after receiving HPV vaccine for 20 sec. drop in BP 60/38 - Rise in pulse 110 BP 82/58 P. 67 BP 110/68 P: 80. Controlled SpO2/Pulse/BP for 30 min. Gave orange juice. Pt claims not to have eaten - possibly related.
Patient fully vaccinated (Moderna) but not boosted admitted to the hospital on 02/09/22 with COVID-19 and associated symptoms. Patient was discharged on 02/11/22.
This case was reported by a healthcare professional and described the occurrence of pain underarm in a subject of unspecified age and gender who was vaccinated with BOOSTRIX (GlaxoSmithKline). On an unspecified date the subject received unspecified dose of BOOSTRIX. It was reported that the subject was experiencing underarm pain a few days after receiving BOOSTRIX. The nurse had not yet spoken with the subject and did not have more detail to provide at the time of reporting. Within days of vaccination with BOOSTRIX, the subject experienced pain underarm. At the time of reporting the outcome of the event was unspecified.
Sore arm; Other stuff; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) and VACCINATION COMPLICATION (Other stuff) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm) and VACCINATION COMPLICATION (Other stuff). At the time of the report, PAIN IN EXTREMITY (Sore arm) and VACCINATION COMPLICATION (Other stuff) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product information was provided.  Treatment information was not provided.
Approximately 3-4 weeks after receiving 2nd vaccination, she developed personality changes consisting of memory difficulties and progressing to symmetrical, ascending lower extremity weakness and associated diarrhea.  Ultimately she was hospitalized with profound hyponatremia sodium of 115,  new onset anemia hemoglobin of 9 and progressive thrombocytopenia as low as 15k.